Drug Trial Radar · NCT06934538
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jun 17, 2025
Primary completion
Jun 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Brenus PharmaIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of STC-1010 associated with GM-CSF and cyclophosphamide immunostimulant (IS) regimen administered with standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab) to participants with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) colorectal cancer (CRC). The trial will be conducted in two parts: * A Phase I consisting of a dose escalation part and small expansion part to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D) and safety profile of the STC-1010 + IS regimen administered with SOC therapy. Approximately 21 to 33 participants will be included in this phase in Europe. * A Phase IIA consisting of the expansion stage of the study which will further evaluate the clinical efficacy and safety of STC-1010 on a larger number of participants treated at the identified RP2D. Approximately 57 to 60 participants will be enrolled in total in 2 different arms. Multi-site recruitment will take place in Europe and in the US.
Conditions
- Unresectable Metastatic Colorectal Cancer
- Unresectable Locally Advanced Colorectal Cancer
Interventions
STC-1010 + IS regimen + SOC therapyBiological
STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: To determine overall safety profile, recommended Phase 2 dose (RP2D) and maximum tolerated dose (MTD)Time frame: 28 days
- Phase 2A: To determine the clinical efficacy by Progression Free Survival (PFS) rateTime frame: 12 months
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Johns Hopkins
Baltimore, Maryland · Not yet recruiting
Institut Jules Bordet
Brussels, Belgium · Recruiting
Institut Bergonié
Bordeaux, France · Recruiting
Centre Georges François Leclerc (CGFL)
Dijon, France · Recruiting
Centre Léon Bérard (CLB)
Lyon, France · Recruiting
Hospices Civils de Lyon (HCL)
Lyon, France · Recruiting
Institut du Cancer de Montpellier (ICM)
Montpellier, France · Recruiting
Centre Hospitalier Universitaire de Poitiers (CHU)
Poitiers, France · Not yet recruiting
Institut Gustave Roussy (IGR)
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.